Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Profound Medical ( (TSE:PRN) ) has provided an update.
On May 14, 2026, Profound Medical announced that its TULSA Procedure will be featured in four oral presentations at the American Urological Association’s Annual Meeting in Washington, D.C., on May 16, 2026, within a session on localized prostate cancer ablative therapy. The talks, led by clinicians from Mayo Clinic, Turku University Hospital, and Sapporo Hokuyu Hospital, will showcase multicenter registry data, phase 2 trial outcomes, and real-world evidence on safety, efficacy, MRI characteristics, and functional preservation associated with MRI-guided transurethral ultrasound ablation.
During AUA2026, Profound will also demonstrate its TULSA-PRO system and an example of a Siemens MAGNETOM Free.Max MRI at its booth, underscoring its ambition to provide a comprehensive interventional MRI solution for prostate ablation. In parallel, the company is launching an initiative to explore integrating PSMA PET molecular imaging with TULSA-PRO treatment planning, a move that could improve intent-to-treat decisions, enable more precise, patient-tailored ablation strategies, and potentially enhance Profound’s competitive positioning in image-guided prostate cancer therapy.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$12.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on PRN Stock
According to Spark, TipRanks’ AI Analyst, PRN is a Neutral.
The score is held back primarily by weak financial performance—large ongoing losses and significant cash burn despite strong gross margins and revenue growth. Offsetting this, the latest earnings call provided constructive guidance with a specific profitability roadmap and improving cash-burn trajectory, while technical indicators show modest, neutral-to-positive momentum. Valuation remains constrained by negative earnings and the absence of dividend support.
To see Spark’s full report on PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in interventional MRI procedures for minimally invasive, incision-free therapies. Its flagship TULSA-PRO platform enables MRI-guided transurethral ultrasound ablation of prostate tissue, while its Sonalleve system targets bone metastases, desmoid tumors, osteoid osteoma, and gynecologic conditions such as uterine fibroids and adenomyosis across major global markets.
The company’s technologies are cleared or approved in the United States, Europe, Canada, China, Saudi Arabia, and other jurisdictions, with TULSA-PRO authorized for prostate tissue ablation and Sonalleve approved for select oncologic and gynecologic indications. By leveraging real-time MRI guidance, Profound aims to expand access to precise, personalized, non-surgical treatment options that can reduce side effects and recovery times compared with traditional surgery or radiation.
Profound’s approach focuses on enabling physicians to see, ablate, and confirm therapy in real time to tailor treatments ranging from whole-gland to focal interventions. This positioning supports growing demand for targeted, organ-sparing oncology solutions and may strengthen the company’s role in the evolving market for MRI-guided, image-based therapies.
Average Trading Volume: 18,372
Technical Sentiment Signal: Buy
Current Market Cap: C$351.4M
Find detailed analytics on PRN stock on TipRanks’ Stock Analysis page.